- Home
- CELC vs DSP Comparison
CELC vs DSP Comparison
Compare CELC & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- DSP
- Stock Information
- Founded
- CELC 2011
- DSP 1999
- Country
- CELC United States
- DSP United States
- Employees
- CELC N/A
- DSP N/A
- Industry
- CELC Medical Specialities
- DSP EDP Services
- Sector
- CELC Health Care
- DSP Technology
- Exchange
- CELC Nasdaq
- DSP Nasdaq
- Market Cap
- CELC 327.3M
- DSP 291.3M
- IPO Year
- CELC 2017
- DSP 2021
- Fundamental
- Price
- CELC $10.24
- DSP $12.80
- Analyst Decision
- CELC Strong Buy
- DSP Strong Buy
- Analyst Count
- CELC 6
- DSP 7
- Target Price
- CELC $30.17
- DSP $22.00
- AVG Volume (30 Days)
- CELC 392.7K
- DSP 388.9K
- Earning Date
- CELC 05-14-2025
- DSP 04-29-2025
- Dividend Yield
- CELC N/A
- DSP N/A
- EPS Growth
- CELC N/A
- DSP N/A
- EPS
- CELC N/A
- DSP 0.14
- Revenue
- CELC N/A
- DSP $289,235,000.00
- Revenue This Year
- CELC N/A
- DSP $18.18
- Revenue Next Year
- CELC N/A
- DSP $16.35
- P/E Ratio
- CELC N/A
- DSP $90.43
- Revenue Growth
- CELC N/A
- DSP 29.74
- 52 Week Low
- CELC $7.58
- DSP $7.77
- 52 Week High
- CELC $19.77
- DSP $26.33
- Technical
- Relative Strength Index (RSI)
- CELC 54.38
- DSP 43.43
- Support Level
- CELC $7.58
- DSP $12.53
- Resistance Level
- CELC $10.48
- DSP $13.22
- Average True Range (ATR)
- CELC 1.04
- DSP 1.05
- MACD
- CELC 0.17
- DSP 0.25
- Stochastic Oscillator
- CELC 80.01
- DSP 53.33
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.